ELAVL1 and prostate carcinoma: In prostate cancer, METTL3 improves the YTHDF2–HNRNPD-recognized degradation of ubiquitin-specific peptidase 4 (USP4) by mediating m6A modification on A2696 and then maintains the ubiquitin of ELAV-like RNA-binding protein 1 (ELAVL1), giving rise to the migration and invasion of cancer cells [78].